Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HS1 trial of povorcitinib in moderate to severe hidradenitis suppurativa
NL-OMON59025Phase 3Completed
- Sponsor
- Incyte
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Povorcitinib with Placebo (2 arms). Primary endpoint: Hidradenitis Suppurativa Clinical Response at Week 12. Started Jul 2023; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON59025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59025.